Automated Dispensing Machines Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | Omnicell, BD, Swisslog, ScriptPro, Capsa Healthcare
Coherent Market Insights has released a comprehensive report on the Automated Dispensing Machines Market, forecasting strong growth through 2033. The report analyzes industry trends, competitive dynamics, and regional performance, featuring key players like Omnicell, BD, and Swisslog. It offers crucial insights for business leaders, investors, and strategists, covering market segmentation, research methodology, and strategic recommendations.
When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight
BD (Becton, Dickinson and Company) has launched the HemoSphere Stream™ Module, an innovation that provides continuous, noninvasive visibility into patients' blood pressure. This module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff to compatible patient monitors, helping clinicians identify hemodynamic changes that might be missed by intermittent readings. The system aims to improve patient safety by enabling earlier detection and treatment of conditions like intraoperative hypotension.
BD Launches HemoSphere Stream Module for Continuous Blood Pressure Monitoring
BD has launched its HemoSphere Stream™ Module, a new noninvasive technology for continuous blood pressure monitoring. This module, used with the VitaWave™ Plus Finger Cuff, provides real-time arterial waveform data, improving patient safety by allowing earlier detection of hemodynamic changes. The innovation aims to enhance care quality and solidify BD's leadership in medical technology.
Blood pressure checks every 3–5 minutes leave gaps; BD offers a live view
BD (Becton, Dickinson and Company) has launched the HemoSphere Stream™ Module, a new device that provides continuous, noninvasive, beat-to-beat arterial waveform data to compatible bedside monitors. This system, used with the VitaWave™ Plus Finger Cuff, aims to eliminate blind spots from intermittent blood pressure checks, typically taken every 3-5 minutes, and enhance patient safety by allowing for earlier detection and treatment of hemodynamic changes. The technology has been validated against arterial line measurements and supports APSF recommendations for continuous noninvasive hemodynamic monitoring, particularly important during and after surgery.
When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight
BD (Becton, Dickinson and Company) has launched the HemoSphere Stream™ Module, a new innovation designed to provide clinicians with continuous, noninvasive visibility into patients' blood pressure. This module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, aiming to close gaps between intermittent readings. The system, comprising the HemoSphere Stream™ Module and VitaWave™ Plus Finger Cuff, is intended to enhance patient safety by improving the detection and treatment of hemodynamic changes such as intraoperative hypotension.
Is Axogen (AXGN) Quietly Redefining Nerve Repair Moats With Avance and New Portfolio Backing?
TimesSquare Capital Management recently added Axogen (AXGN) to its U.S. Small Cap Growth Strategy after the company reported strong fourth-quarter 2025 revenue growth, driven by its peripheral nerve repair portfolio. A key factor is Axogen's Avance Nerve Graft, the only FDA-approved implantable biological nerve allograft, which recently received FDA approval for its Biologics License Application. This strengthens Axogen's position in the peripheral nerve regeneration market, though it introduces new operational and compliance demands.
BD Rolls Out Next-Gen Medication Dispensing System Across Europe
BD has launched its BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform in Europe, combining automation with AI-powered insights to enhance medication management, streamline workflows, and improve patient care. This system aims to boost operational efficiency and medication availability across European hospitals. Despite a recent stock dip, the company expects this move to strengthen its competitive position in the digital healthcare sector due to increased demand for its innovative solutions.
Cancer test developer Biodesix brings 7 studies to AACR meeting
Biodesix (Nasdaq: BDSX) announced it will present seven abstracts, including two oral sessions, at the AACR Annual Meeting in San Diego from April 17–22, 2026. The presentations will cover various aspects of cancer diagnostics, including blood- and tissue-based testing, tumor and immune profiling, and multi-omic molecular residual disease (MRD) pipeline development. This includes novel proteomic and genomic approaches leveraging technologies like mass spectrometry, Bio-Rad ddPCR, and Thermo Fisher Ion AmpliSeq and Ion Torrent Genexus workflows, with collaborators such as Memorial Sloan Kettering Cancer Center co-presenting data.
Kevin Hern makes significant sales in Accenture, Texas Instruments, and SmartStop Self Storage stocks
Kevin Hern, a U.S. Representative from Oklahoma, has made significant stock sales through family trusts in Accenture, Texas Instruments, and SmartStop Self Storage REIT, among others. The Accenture sales ranged from $250,001 to $500,000, while Texas Instruments and SmartStop Self Storage sales were each between $500,001 and $1,000,000. These transactions occurred in March 2026.
Asia Pacific Pharmacy Automation Market Is Going to Boom |• Omnicell • McKesson Corporation
Worldwide Market Reports has released a new research study on the "Asia Pacific Pharmacy Automation Market," forecasting its growth from 2026 to 2033. The report offers an in-depth analysis of market drivers, challenges, competitive landscape, and segmentation, utilizing both primary and secondary research. Key players like Omnicell and McKesson Corporation are highlighted, and the study provides insights for stakeholders to make informed investment decisions.
Evercore ISI upgrades Waters stock rating on achievable targets
Evercore ISI has upgraded Waters Corp. (NYSE:WAT) stock rating to Outperform from In Line, setting a price target of $350.00, citing confidence in the company's first-quarter numbers and a favorable second-half turnaround. This upgrade comes despite some analyst concerns regarding the stock's valuation and recent acquisitions. The company trades at $304.24 with a market cap of $29.85 billion.
Assessing Baxter (BAX) Valuation After Launch Of IV Verify Line Labeling System
Baxter International recently launched its IV Verify Line Labeling System, an automation tool for IV line identification, medication safety, and nurse workflow. Despite this innovation and a 5.6% gain in the last 7 days, the stock has experienced a 41.0% loss over the past year. Simply Wall St's analysis suggests Baxter is currently undervalued by 23% with a fair value of $21.63, driven by ongoing portfolio optimization, cost reductions, and new leadership, but potential risks from margin pressures and product issues remain.
Pleural Diseases Market Set to Boom Rapidly by 2033 |Bristol Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc
The global Pleural Diseases Market is projected to grow from USD 5.76 billion in 2025 to USD 9.37 billion in 2032, exhibiting a CAGR of 7.2%. This growth is driven by rapid innovation and shifting regional dynamics, with key players including Bristol Myers Squibb, Merck & Co., Inc., and GlaxoSmithKline plc. The market is segmented by disease type, diagnostic tools, treatment modalities, and end-users, and the report provides strategic insights for stakeholders.
Thermo Fisher Microscopes: Precision in Scientific Imaging
This article details how Thermo Fisher microscopes are crucial for scientific imaging across various research and industrial applications. It highlights their advanced optical and electron models, cutting-edge features like high-resolution optics, fluorescence capabilities, and automation. The article also discusses their market relevance, competitive landscape, ongoing innovations, and significant impact on global health and scientific discovery.
Becton, Dickinson declares $1.04 dividend
Becton, Dickinson (BDX) has declared a quarterly dividend of $1.04 per share, payable on March 29, 2024, to shareholders of record as of March 8, 2024. This announcement reflects the company's consistent return of value to its shareholders.
Becton, Dickinson declares $1.04 dividend
Becton, Dickinson (BDX) has declared a quarterly dividend of $1.04 per share, maintaining its previous payout. The dividend is payable on March 29, 2024, to shareholders of record as of March 8, 2024. This announcement signals continued shareholder returns from the medical technology company.
Global Clinical Drainage Supplies Market Dominated by North America as Cardinal Health and Medline Expand Products
The global clinical drainage supplies market is transitioning to a critical infrastructure layer in healthcare, valued at USD 4.5 billion in 2026 and projected to reach USD 8.8 billion by 2036 with a CAGR of 6.9%. Growth is driven by standardization, infection control, and the expansion of integrated kits, with North America dominating and India emerging as the fastest-growing market. Key players like Becton, Dickinson and Company, Cardinal Health, Medtronic, Teleflex, and Getinge compete on portfolio coverage and supply continuity.
Global Clinical Drainage Supplies Market Dominated by North America as Cardinal Health and Medline Expand Products
The global clinical drainage supplies market is projected to grow from USD 4.5 billion in 2026 to USD 8.8 billion by 2036, at a CAGR of 6.9%. This growth is driven by the increasing need for protocol standardization and infection control in surgical and post-acute care, with reliability and seal integrity being key factors for procurement. North America, alongside emerging markets like India and Brazil, is a significant driver of this expansion, while key players such as Becton, Dickinson and Company, and Cardinal Health continue to dominate.
Assessing Becton Dickinson's Valuation After Recent Share Price Weakness And Planned Biosciences Separation
Becton Dickinson (BDX) has experienced recent share price weakness, with declines over the past month and three months, despite a strong narrative suggesting undervaluation. The company is poised for a significant transformation with the planned separation of its Biosciences and Diagnostic Solutions business, aiming for a pure-play medical technology focus. While the fair value is estimated at $196.08, indicating a potential 21.2% undervaluation, investors are cautioned to consider risks like trade pressures and execution challenges related to the separation.
Becton, Dickinson and Company (NYSE:BDX) Given Average Rating of "Hold" by Analysts
Becton, Dickinson and Company (NYSE:BDX) has received an average "Hold" rating from analysts, with a consensus 12-month price target of $191.6154. Recent insider transactions show directors and EVPs selling shares, while institutional investors have significantly increased their positions. The company reported quarterly earnings that beat estimates but revenue was below expectations, and it recently declared a quarterly dividend of $1.05 per share.
A Look At West Pharmaceutical Services (WST) Valuation After New Dublin Expansion For Injectable Treatments
West Pharmaceutical Services (WST) has expanded its Dublin site to support high-volume injectable treatments for diabetes and obesity. Despite recent share price pressure, analysts suggest the stock is undervalued, with a fair value of $338.57 against a current trading price of US$254.80. However, its high P/E ratio compared to the industry indicates a potential valuation risk if market sentiment shifts.
ResMed Inc. (RMD) stock price, news, quote and history
This article provides comprehensive financial data, news, and historical information for ResMed Inc. (RMD). It includes real-time stock quotes, key statistics, performance over various periods, an overview of the company's operations in medical devices and cloud-based software, and analyst insights. The report also lists financial highlights, profitability metrics, and allows for comparison with similar companies in the Medical Instruments & Supplies industry.
Biopsy Devices Market to Reach US$ 6.85 Billion by 2033 at 10.15% CAGR; North America Leads with 42% Share - Key Players: Becton, Dickinson and Company, Hologic Inc., Boston Scientific Corporation
The global biopsy devices market is projected to reach US$ 6.85 billion by 2033, growing at a compound annual growth rate (CAGR) of 10.15% from US$ 2.68 billion in 2025. This growth is primarily driven by the increasing prevalence of cancer and other chronic diseases, alongside advancements in minimally invasive and image-guided biopsy technologies. North America is expected to maintain its leading position in the market, holding a 42% share, due to its advanced healthcare infrastructure and early adoption of innovative diagnostic tools.
HF Advisory Group LLC Has $6.64 Million Position in Becton, Dickinson and Company $BDX
HF Advisory Group LLC significantly increased its stake in Becton, Dickinson and Company (BDX) by 559.3% in Q4, holding 34,230 shares valued at $6.643 million. BDX surpassed Q4 earnings expectations with $2.91 EPS and $5.25 billion revenue, and analysts currently rate the stock as "Hold" with a target price of $191.62. The company also announced a quarterly dividend of $1.05 per share and a $10 million share repurchase plan.
BD Launches AI-Enabled Medication Dispensing System to the European Market
BD (Becton, Dickinson and Company) has launched its AI-enabled BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform in Europe. This system aims to modernize medication management, improve efficiency, and enhance patient care through advanced automation and AI-driven insights. The solution offers increased medication storage capacity, enhanced security features, and will extend its AI-powered analytics to European hospitals next year, leveraging AWS European Sovereign Cloud for data insights.
BD Launches AI-Enabled Medication Dispensing System to the European Market
BD (Becton, Dickinson and Company) has launched its BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform in Europe. This new AI-enabled medication dispensing system aims to modernize medication management, improve efficiency, and enhance patient care by providing quick, reliable access to medications at the point of care. The system offers advanced automation, AI-driven insights, enhanced security features for controlled substances, and will leverage the AWS European Sovereign Cloud to meet digital sovereignty needs.
BD Launches AI-Enabled Medication Dispensing System to the European Market
BD (Becton, Dickinson and Company) has launched its new AI-enabled medication dispensing system, comprising the BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform, in Europe. This system aims to modernize medication management by integrating advanced automation and AI-driven insights to enhance efficiency, strengthen inventory control, and improve patient safety. The technology will help clinicians reduce disruptions, optimize medication availability, and minimize waste, ultimately allowing more focus on patient care.
Resmed to post quarterly results after market close on April 30
ResMed (NYSE: RMD) announced it will release its third-quarter fiscal year 2026 financial and operational results on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, which will be accessible via its investor relations website, with replays also available. The announcement emphasizes the company's consistent practice of providing transparency regarding its financial disclosures.
The Evolution of a MedTech Giant: A Deep Dive into Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company (BDX) has transformed into a "pure-play" medical technology entity after spinning off its Biosciences and Diagnostic Solutions unit and merging it with Waters Corporation. The company is now focused on medical delivery, interventional surgery, and connected care, aiming for high-margin software and automated systems. Despite past stock volatility and underperformance, BD’s financial profile shows strength, and it is positioned for growth through its focus on "Smart Connected Care" and addressing healthcare labor shortages and the aging population.
Live Cell Imaging Market Set to Boom Rapidly by 2033| Thermo Fisher Scientific Inc. • Merck KgaA • PerkinElmer Inc
The Live Cell Imaging market is expected to grow significantly, from US$ 1,924.4 Mn in 2025 to US$ 2,921.9 Mn by 2032, at a CAGR of 7.2%. This report provides an in-depth analysis of market dynamics, key players such as Thermo Fisher Scientific, Merck KgaA, and PerkinElmer Inc., regional trends, and growth opportunities with forecasts up to 2033. It serves as a strategic guide for stakeholders with competitive analysis, market segmentation, and crucial insights to foster sustainable growth.
Qiagen N.V. Stock: Leader in Molecular Diagnostics Faces CEO Transition Amid Steady Growth Outlook
Qiagen N.V. (ISIN: NL0012169213), a prominent molecular diagnostics leader, is undergoing a CEO transition while maintaining its 5% growth target for the year. North American investors are advised to monitor leadership changes, new product launches, and the company's strategic focus on innovation and sustainability. The company's resilience, diversified portfolio, and strong position in genomics tools make it an appealing option despite sector headwinds.
Baxter’s IV Verify Launch Tests Medication Safety Strategy And Hospital Traction
Baxter International has launched the IV Verify Line Labeling System, an automated solution developed in partnership with Vigilant Software to enhance medication safety and nurse workflow in clinical settings. This new product addresses long-standing challenges with inconsistent IV labeling and aims to support Baxter's broader hospital and medication delivery market positioning, despite the company's significant share price decline over recent years. The success of IV Verify will depend on its adoption by hospitals, integration into existing systems, and its ability to demonstrate value in terms of safety compliance and nurse efficiency.
BDX: 2026 MedTech Setup And Tuck In M&A Will Support Upside
Becton Dickinson (BDX) is positioned for upside in 2026, driven by a constructive MedTech environment and strategic tuck-in M&A. While analysts have mixed views, with some trimming price targets due to valuation concerns and others raising targets based on execution confidence, the company's focus on high-growth, high-margin areas and recent product launches are seen as positive drivers. The fair value has been slightly trimmed, but profitability assumptions have increased, suggesting a balanced outlook.
Top Players and Market Competition in the In Situ Hybridization Industry
The in situ hybridization market is projected to reach $3.08 billion by 2030, growing at an 11.3% CAGR, driven by personalized medicine, AI-driven analysis, and genomic research. Key players like Thermo Fisher Scientific and Danaher Corporation are shaping the industry, with a focus on innovations such as Hybridization Chain Reaction RNA Chromogenic in situ Hybridization (HCR RNA-CISH). The market is segmented by product types, techniques, probe types, applications, and end-users, highlighting its specialized and evolving nature.
Infectious Disease Diagnostics Testing Market Overview, Key Trends, and Major Player Analysis
The infectious disease diagnostics testing market is projected to reach $65.49 billion by 2030, growing at a CAGR of 9.0%. This growth is driven by increasing global health challenges, demand for rapid diagnostic tools, and investments in healthcare. Key trends include stronger demand for early detection, wider adoption of point-of-care testing, and increased use of molecular diagnostics.
Growth Patterns, Segment Analysis, and Competitive Approaches Influencing the Dental Preventive Supplies Market
The global dental preventive supplies market is projected to reach $6.57 billion by 2030, growing at a CAGR of 5.6% due to increased oral health awareness, product innovations, and expanding dental services. Key players like Procter & Gamble and Colgate-Palmolive are driving growth with new products, such as antibacterial oral care regimens. The market is segmented by product type, material, distribution channel, application, and end-user, reflecting diverse consumer needs.
Evotec to discuss 2025 results and business update on April 8
Evotec (NASDAQ: EVO) has announced it will host a webcast and conference call on April 8, 2026, to discuss its fourth-quarter and full-year 2025 financial results and provide a business update. The live webcast is scheduled for 2:00 pm CEST (8:00 am EDT), with registration required for access to audio and presentation slides. Investors will be keen to see how recent positive developments, including BARDA funding, a Bristol Myers Squibb milestone, and a Gates Foundation AI grant, have impacted the company's financial performance and strategic trajectory.
BD Launches AI-Enabled Medication Dispensing System to the European Market
BD (Becton, Dickinson and Company) has launched its AI-enabled BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform in Europe. This system aims to modernize medication management, improve efficiency, and enhance patient care through advanced automation and AI-driven insights. The solution offers increased medication storage capacity, enhanced security features, and uses AWS European Sovereign Cloud to meet digital sovereignty needs for EU healthcare systems.
BD Launches AI-Enabled Medication Dispensing System to the European Market
BD (Becton, Dickinson and Company) has launched its AI-enabled BD Pyxis™ Pro Dispensing Solution and BD Incada™ Connected Care Platform in Europe. This system aims to modernize medication management, improve efficiency, and enhance patient care through advanced automation and AI-driven insights. The solution offers increased medication storage capacity, enhanced security features, and enterprise-wide visibility into inventory, leveraging the AWS European Sovereign Cloud for digital sovereignty needs.
Evotec taps $7 billion dealmaker to build its global commercial team
Evotec (NASDAQ:EVO) has appointed Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer, effective April 1, 2026. Dr. Khan brings over 15 years of international leadership experience in biotech, CRO, and AI-driven platform businesses, with a notable track record of closing over $7 billion in deals. His role will focus on building a globally integrated commercial organization to drive sustainable growth and enhance customer value for Evotec.
Baxter’s IV Verify Launch Tests Medication Safety Strategy And Hospital Traction
Baxter International (NYSE:BAX) has launched the IV Verify Line Labeling System, an automated solution developed with Vigilant Software to enhance medication safety and streamline nurse workflows in hospitals. This product aims to address challenges with inconsistent IV labeling and medication errors. While Baxter's shares have seen significant declines, the company hopes IV Verify will strengthen its position in hospital markets, though its commercial impact and adoption trends remain to be seen, presenting both risks and potential rewards for the company and investors.
Waters Corp (WAT) Expands After BD Diagnostic Solutions Acquisition
Waters Corporation (WAT) is actively integrating its acquisition of BD Diagnostic Solutions and focusing on development ambitions, as discussed at the TD Cowen 46th Annual Health Care Conference. The company forecasts 6.25% organic growth in its core business for 2026, driven by strong performance in chemistry and services, though it anticipates some near-term headwinds in China. Waters plans to boost EPS growth and margin expansion through cost management and tariffs, while heavily investing in bioseparations.
Trends in Growth, Segment Analysis, and Competitive Approaches
The hand-held surgical instruments market is projected to reach $12.96 billion by 2030, growing at an 11.5% CAGR, driven by advanced surgical techniques, infection prevention, and outpatient surgeries. Key players include Johnson & Johnson, B. Braun Melsungen AG, and Zimmer Biomet Holdings Inc., with significant innovation seen in precision tools and ergonomic designs. Recent acquisitions, such as STERIS PLC's purchase of Becton, Dickinson and Company's surgical assets, are shaping the competitive landscape.
Pacific Capital Partners Ltd Buys 8,250 Shares of Becton, Dickinson and Company $BDX
Pacific Capital Partners Ltd significantly increased its stake in Becton, Dickinson & Co. (BDX) by 28.2% in Q4, making it their largest holding. This comes as Becton, Dickinson reported strong Q4 earnings, surpassing analyst expectations, and announced a quarterly dividend and share repurchase authorization. Despite mixed analyst ratings, institutional investors continue to show strong interest in the medical instruments supplier.
Becton, Dickinson and Company (NYSE:BDX) Short Interest Down 16.8% in March
Becton, Dickinson and Company (NYSE:BDX) experienced a 16.8% decrease in short interest in March, totaling 11.47 million shares. The company recently surpassed quarterly earnings estimates with an EPS of $2.91 and revenue of $5.25 billion, and announced a $10 million share buyback alongside a quarterly dividend of $1.05 per share. Analysts have a consensus "Hold" rating on the stock with a target price of $191.62.
In-Depth Examination of Segments, Industry Developments, and Key Competitors in the Biobank Equipment Market
The biobank equipment market is projected to reach $6.5 billion by 2030, growing at a CAGR of 9.2%, driven by automation, AI integration, and the needs of regenerative medicine. Key trends include AI-powered sample management and IoT-enabled monitoring, with top players like Thermo Fisher Scientific and Merck KGaA leading innovation. The market is segmented by product type, sample type, storage system type, application areas, and end-user groups, with a focus on sustainable, automated solutions for secure and efficient biological sample preservation.
Baxter Foundation Therapy Animal Push And What It Means For Investors
The Baxter Foundation has partnered with Pet Partners for a two-year pilot program to expand therapy animal visits in U.S. healthcare settings, aiming to reach 100,000 patients and healthcare workers. While the direct financial impact on Baxter International (NYSE: BAX) is uncertain, this initiative could strengthen its relationships with healthcare providers and patients. For investors, this philanthropic effort is a reputational boost amidst concerns about the company's financial performance and legal issues, reinforcing its position in the broader healthcare ecosystem.
ICU Medical (FRA:IC7) Issuance of Debt : €0 Mil (TTM As of Dec. 2025)
ICU Medical (FRA:IC7) reported an issuance of debt of €0 million for the trailing twelve months (TTM) ended December 2025 and for the quarter ended December 2025. GuruFocus rates ICU Medical with a GF Score of 84/100 and considers the stock "Fairly Valued" with a GF Value of €110.46 against a current price of €107.00, noting 4 warning signs. The company is a key player in infusion therapy systems and supplies, generating over 60% of its sales domestically in the US.
Microbot Medical (HAM:CY9D) Land And Improvements : €0.00 Mil (As of Dec. 2025)
This article reports that Microbot Medical (HAM:CY9D) has €0.00 million in Land And Improvements as of December 2025. GuruFocus rates the company with a GF Score of 43/100 and notes 2 warning signs for investors. The article provides historical data and a definition of "Land And Improvements" for context.
Avity Investment Management Inc. Acquires 11,186 Shares of Becton, Dickinson and Company $BDX
Avity Investment Management Inc. increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 7.1% in the fourth quarter, purchasing an additional 11,186 shares and bringing its total holdings to 169,364 shares worth approximately $32.9 million. This makes BDX Avity's 18th largest holding, representing about 2.3% of its portfolio. Other institutional investors also made significant moves, with institutional ownership of BDX now standing at 86.97%. The company recently beat quarterly earnings expectations, provided strong FY2026 guidance, and announced a $10 million share buyback and a $1.05 quarterly dividend.
